No Improvement in OS or PFS from Sacituzumab Govitecan Compared with Chemotherapy In Pretreated Patients with Advanced Urothelial Cancer By Ogkologos - March 24, 2025 888 0 Facebook Twitter Google+ Pinterest WhatsApp Findings from the TROPiCS-04 study Source RELATED ARTICLESMORE FROM AUTHOR FDA Approves Allogeneic Regulatory T Cell-Based Immunotherapy with HSPC and T Cells-vldq for Use in Matched Donor HSCT for Adult Patients with Haematologic Malignancies Combination of mFOLFOX6/Bevacizumab Plus Atezolizumab Prolongs PFS Compared with Atezolizumab in First-Line Treatment of dMMR/MSI-H mCRC Use of YEARS Algorithm, D-dimer Levels, and Performing Risk-Dependent CT Pulmonary Angiography is Safe in Patients with Cancer and Suspected Pulmonary Embolism MOST POPULAR Imetelstat Shows Durable Transfusion Independence and Disease-Modifying Activity in Heavily Transfused... December 11, 2023 Using a Blood Test to Select Treatments for Advanced Gastrointestinal Stromal... January 23, 2023 Rebuilding My Life After Cancer and Intensive Treatment: A Survivor’s Story February 9, 2023 Benefits of Regular Breast Cancer Screening Outweigh Risks of Overdiagnosis, New... May 18, 2021 Load more HOT NEWS How Exercise Can Help You Cope With the Mental and Emotional... Single-Fraction SABR Preferred from Resource and Patient Perspectives for Pulmonary Oligometastases Individualised Nutritional Support Reduce the Risk of Mortality in Cancer Patients... Systemic Aging Associated with a Higher Risk of Early-Onset Solid Cancers
